Affiliation: Harvard University
- Accounting for death as a competing risk in cancer-associated thrombosis studiesFederico Campigotto
Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215 5450, USA
Thromb Res 129:S85-7. 2012..This review describes the theoretical and mathematical basis for estimating the cumulative incidence function by the competing risk model for the analysis of VTE outcomes in cancer-associated thrombosis...
- A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancerNathan J Robison
Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts Division of Pediatric Hematology Oncology, Department of Pediatrics, Boston Children s Hospital, Boston, Massachusetts
Pediatr Blood Cancer 61:636-42. 2014..We undertook a prospective, open-label, single-arm, multi-institutional phase II study to evaluate the efficacy of a "5-drug" oral regimen in children with recurrent or progressive cancer...
- Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)Jeffrey I Zwicker
Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
Br J Haematol 160:530-7. 2013..Enoxaparin demonstrated a clear trend towards reducing the rate of VTE in patients with elevated levels of TFMP, with an overall rate of VTE similar in magnitude to the lower TFMP group...
- Recurrence of Venous Thromboembolism in Patients With Cancer Treated With WarfarinAriela L Marshall
Department of Hematology and Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Clin Appl Thromb Hemost 21:632-8. 2015..0% on dalteparin, and 14.3% on fondaparinux (P = .089). In a dedicated anticoagulation clinic, specific for patients with cancer, warfarin may be an acceptable treatment for first thrombotic events in patients with cancer...
- Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemiaOlga K Weinberg
Department of Pathology, Children s Hospital Boston, Boston, MA, USA
Mod Pathol 28:965-76. 2015....
- Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter studyJeffrey I Zwicker
Jeffrey I Zwicker, Adam Rojan, and Renee Funches, Beth Israel Deaconess Medical Center and Harvard Medical School Federico Campigotto and Donna Neuberg, Dana Farber Cancer Institute, Boston, MA Nadia Rehman and Ted Wun, University of California at Davis School of Medicine Nadia Rehman and Ted Wun, VA Northern California Health Care System, Sacramento, CA Gregory Connolly, University of Rochester Medical Center, Rochester, NY Jonathan Webster and Michael B Streiff, Johns Hopkins University School of Medicine, Baltimore, MD Anita Aggarwal, Dalia Mobarek, Charles Faselis, and Frederick R Rickles, Veterans Administration Medical Center and The George Washington University, Washington, DC and Alok A Khorana, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
J Clin Oncol 32:1792-6. 2014..Despite strong recommendations in numerous clinical practice guidelines, retrospective studies have shown that pharmacologic thromboprophylaxis is underutilized in hospitalized patients with cancer...
- Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysisAndrew M Brunner
Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts, USA
Cancer 119:2620-9. 2013..The authors performed a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database to assess 5-year overall survival (OS) in various patient age groups...